An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

KRAS-driven cancers remain refractory to current clinical therapies. In this study, the authors show that lung and pancreatic cancers expressing oncogenic KRAS can be targeted by genetic inhibition of FOSL1, which involves downregulation of genes of the mitotic machinery.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Adrian Vallejo, Naiara Perurena, Elisabet Guruceaga, Pawel K. Mazur, Susana Martinez-Canarias, Carolina Zandueta, Karmele Valencia, Andrea Arricibita, Dana Gwinn, Leanne C. Sayles, Chen-Hua Chuang, Laura Guembe, Peter Bailey, David K. Chang, Andrew Biankin, Mariano Ponz-Sarvise, Jesper B. Andersen, Purvesh Khatri, Aline Bozec, E. Alejandro Sweet-Cordero, Julien Sage, Fernando Lecanda, Silve Vicent
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/b67e9794d6104499b87c9422aa01ff4a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:KRAS-driven cancers remain refractory to current clinical therapies. In this study, the authors show that lung and pancreatic cancers expressing oncogenic KRAS can be targeted by genetic inhibition of FOSL1, which involves downregulation of genes of the mitotic machinery.

Documents similaires